Esther H. Chung

Esther H. Chung

Auto-generated profile, based on publicly available information

Esther H. Chung

Stanford Fertility and Reproductive Health

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2022 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
BPBenjamin J Peipert
Benjamin J Peipert
ECEsther H Chung
Esther H Chung
BHBenjamin S Harris
Benjamin S Harris
TJTarun Jain
Tarun Jain

11 May 2021 in Journal of Assisted Reproduction and Genetics
Verified
Journal Article
Open access
PDF file
ECEsther H. Chung
Esther H. Chung
SLStephanie L. Lim
Stephanie L. Lim
EMEvan Myers
Evan Myers
HMHaley A. Moss
Haley A. Moss
KAKelly S. Acharya
Kelly S. Acharya
Purpose In December 2019, the American Society for Reproductive Medicine designated ovarian tissue cryopreservation (OTC) as no longer experimental and an alternative to oocyte cryopreservation (OC) for women receiving gonadotoxic therapy. Anticipating increased use of OTC, we compare the cost-effectiveness of OC versus OTC for fertility preservation in oncofertility patients. Methods A cost-effectiveness model to compare OC versus OTC was built from a payer perspective. Costs and probabilities were derived from the literature. The primary outcome for effectiveness was the percentage of patients who achieved live birth. Strategies were compared using incremental cost-effectiveness ratios (ICER). All inputs were varied widely in sensitivity analyses. Results In the base case, the estimated cost for OC was $16,588 and for OTC $10,032, with 1.56% achieving live birth after OC, and 1.0% after OTC. OC was more costly but more effective than OTC, with an ICER of $1,163,954 per live birth. In sensitivity analyses, OC was less expensive than OTC if utilization was greater than 63%, cost of OC prior to chemotherapy was less than $8100, cost of laparoscopy was greater than $13,700, or standardized discounted costs were used. Conclusions With current published prices and utilization, OC is more costly but more effective than OTC. OC becomes cost-saving with increased utilization, when cost of OC prior to chemotherapy is markedly low, cost of laparoscopy is high, or standardized discounted oncofertility pricing is assumed. We identify the critical thresholds of OC and OTC that should be met to deliver more cost-effective care for oncofertility patients.

18 April 2020 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Closed access
PDF file
ECEsther H. Chung
Esther H. Chung
SLStephanie L. Lim
Stephanie L. Lim
LHLaura J. Havrilesky
Laura J. Havrilesky
ASAnne Z. Steiner
Anne Z. Steiner
SDS. K. Dotters‐Katz
S. K. Dotters‐Katz

1 August 2017 in Journal of Neurosurgery
Verified
Journal Article
Open access
PDF file
THThu-Trang Hickman
Thu-Trang Hickman
MSMatthew E. Shuman
Matthew E. Shuman
TJTatyana A. Johnson
Tatyana A. Johnson
FYFelix Yang
Felix Yang
RRRebecca R. Rice
Rebecca R. Rice
MJMark D. Johnson
Mark D. Johnson
OBJECTIVE: Idiopathic normal pressure hydrocephalus (iNPH) is characterized by ventriculomegaly, gait difficulty, incontinence, and dementia. The symptoms can be ameliorated by CSF drainage. The object of this study was to identify factors associated with shunt-responsive iNPH.METHODS: The authors reviewed the medical records of 529 patients who underwent shunt placement for iNPH at their institution between July 2001 and March 2015. Variables associated with shunt-responsive iNPH were identified using bivariate and multivariate analyses. Detailed alcohol consumption information was obtained for 328 patients and was used to examine the relationship between alcohol and shunt-responsive iNPH. A computerized patient registry from 2 academic medical centers was queried to determine the prevalence of alcohol abuse among 1665 iNPH patients.RESULTS: Bivariate analysis identified associations between shunt-responsive iNPH and gait difficulty (OR 4.59, 95% CI 2.32–9.09; p < 0.0001), dementia (OR 1.79, 95% CI 1.14–2.80; p = 0.01), incontinence (OR 1.77, 95% CI 1.13–2.76; p = 0.01), and alcohol use (OR 1.98, 95% CI 1.23–3.16; p = 0.03). Borderline significance was observed for hyperlipidemia (OR 1.56, 95% CI 0.99–2.45; p = 0.054), a family history of hyperlipidemia (OR 3.09, 95% CI 0.93–10.26, p = 0.054), and diabetes (OR 1.83, 95% CI 0.96–3.51; p = 0.064). Multivariate analysis identified associations with gait difficulty (OR 3.98, 95% CI 1.81–8.77; p = 0.0006) and alcohol (OR 1.94, 95% CI 1.10–3.39; p = 0.04). Increased alcohol intake correlated with greater improvement after CSF drainage. Alcohol abuse was 2.5 times more prevalent among iNPH patients than matched controls.CONCLUSIONS: Alcohol consumption is associated with the development of shunt-responsive iNPH.

1 January 2021 in Obstetrical & Gynecological Survey
Verified
Journal Article
Closed access
ECEsther H. Chung
Esther H. Chung
BHBenjamin S. Harris
Benjamin S. Harris
SMSuheil J. Muasher
Suheil J. Muasher
JKJeffrey A. Kuller
Jeffrey A. Kuller
Importance: Up to 4% of all births in developed nations involve assisted reproductive technology (ART), along with other fertility treatment modalities. Thus, ART pregnancies constitute an important epidemiologic population with a known increased risk of congenital anomalies. In this review, we summarize current fertility treatment modalities and their associated risk of congenital anomalies. Objective: To review the risk of birth defects among pregnancies conceived with ART and other fertility treatments. Evidence Acquisition: Articles were obtained from PubMed and the American College of Obstetricians and Gynecologists and American Society of Reproductive Medicine committee opinions. Results: In vitro fertilization has been associated with a 25% to 50% increased risk of birth defects, including abnormalities of these organ systems: cardiovascular (25%–40% of anomalies), genitourinary (10%–60%), gastrointestinal (10%–20%), and musculoskeletal (10%–35%). Although the data are mixed, intracytoplasmic sperm injection has also been found to be associated with an increased risk of defects, particularly hypospadias, when compared with conventional in vitro fertilization. The risk among fresh versus frozen cycles and cleavage stage versus blastocyst transfers remains uncertain. There appears to be no significant added risk with preimplantation genetic testing, although more studies are needed. Ovulation induction with oral agents appears safe and not associated with an increased risk of anomalies. Oocyte cryopreservation also appears safe, but the data are still limited, requiring future investigation. Conclusions and Relevance: While the relative risk of birth defects among ART pregnancies is increased when compared with spontaneous conceptions, the absolute risk remains low. There are no standard screening recommendations for ART pregnancies. Per the American College of Obstetricians and Gynecologists, patients who have undergone ART should be counseled regarding the risk of birth defects and available antenatal evaluation, including fetal echocardiogram and detailed ultrasound evaluation. Target Audience: Obstetricians and gynecologists, family physicians. Learning Objectives: Following completion of this CME article, readers should be better able to assess risk factors for birth defects among individuals undergoing fertility treatment; explain available antenatal screening modalities for detection of common birth defects associated with ART; and identify available resources and recommendations on risk factors for birth defects associated with infertility treatment.

1 May 2021 in Journal of Surgical Education
Verified
Journal Article
Closed access
ECEsther H. Chung
Esther H. Chung
TTTracy Truong
Tracy Truong
KJKaren R. Jooste
Karen R. Jooste
JFJonathan E. Fischer
Jonathan E. Fischer
BDBrittany A. Davidson
Brittany A. Davidson